CHAMP (Prostate Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if a combination of chemotherapies and immunotherapies (carboplatin, cabazitaxel, nivolumab and ipilimumab) slows cancer growth in patients with metastatic neuroendocrine or aggressive variant prostate cancer.

We also want to learn about the types of side effects that patients have while they are taking these study drugs together.

What is the Condition Being Studied?

Prostate Cancer (Neuroendocrine or Aggressive Variant)

Who Can Participate in the Study?

Adults with neuroendocrine or aggressive variant prostate cancer who:
- Have not already had an immunotherapy drug to treat their cancer
- Have not already had cabazitaxel

Age Group

What is Involved?

If you join this study you will:
- Get study drugs given to you through a needle in a vein in your arm every 3 weeks
- Have imaging tests
- Have blood and urine tests
- Complete questionnaires

Study Details

Full Title
A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men with Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)
Principal Investigator
Protocol Number
IRB: PRO00106278
NCT: NCT04709276
Phase II
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center